Literature DB >> 21649729

Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography.

E Ryoung Choi1, Yun Hee Chung, Jong Kyun Lee, Kyu Taek Lee, Kwang Hyuck Lee, Dong Wook Choi, Seong Ho Choi, Jin Seok Heo, Kee-Taek Jang, Sang Mo Park, Jae Hoon Lim.   

Abstract

BACKGROUND AND AIM: In patients with hilar cholangiocarcinoma (HC), longitudinal tumor extent is important for curative resection. The purpose of this study was to evaluate the longitudinal extents of HC using transpapillary intraductal ultrasonography (IDUS) for optimal surgical planning.
METHODS: From July 2006 to April 2010, a total of 42 patients with borderline resectable HC were enrolled at Samsung Medical Center, a tertiary referral hospital in Seoul, Korea. All patients were evaluated using multi-detector computed tomography (MDCT), endoscopic retrograde cholangiopancreatography (ERCP) and IDUS. The new modified Bismuth Type (MBT) classification, in which the traditional Bismuth type IV stage is divided into stages IVa and IVb, was used to determine whether the tumor invaded the left lateral section. Among the subtypes of HC, the periductal infiltrative type (PDI) and intraductal papillary neoplasm of the bile duct (IPN-B) were compared. The accuracies of CT, ERCP, and IDUS were assessed through comparison with the postoperative histology findings.
RESULTS: A total of 42 patients were prospectively enrolled, and the tumor extent could be assessed histologically in 30 patients. The accuracies of CT, ERCP, and IDUS were 66.6%, 60%, and 90%, respectively. The accuracy of IDUS was 85.7% in 21 patients with PDI and 100% in nine patients with IPN-B.
CONCLUSIONS: Hilar cholangiocarcinoma staging based on IDUS findings was highly accurate. We therefore highly recommend using IDUS for optimal surgical planning in patients with borderline resectable HC.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21649729     DOI: 10.1111/j.1440-1746.2011.06804.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

1.  Our Rationale of Initiating Neoadjuvant Chemotherapy for Hilar Cholangiocarcinoma: A Proposal of Criteria for "Borderline Resectable" in the Field of Surgery for Hilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Daisuke Morioka; Ryutaro Mori; Yasuhiro Yabushita; Seigo Hiratani; Yohei Ota; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-04       Impact factor: 3.352

Review 2.  Perioperative Management of Hilar Cholangiocarcinoma.

Authors:  Katherine E Poruk; Timothy M Pawlik; Matthew J Weiss
Journal:  J Gastrointest Surg       Date:  2015-05-29       Impact factor: 3.452

Review 3.  Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

Authors:  Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik
Journal:  Langenbecks Arch Surg       Date:  2014-06-25       Impact factor: 3.445

4.  The Impact of MDCT and Endoscopic Transpapillary Mapping Biopsy to Predict Longitudinal Spread of Extrahepatic Cholangiocarcinoma.

Authors:  Kyoji Ito; Yoshihiro Sakamoto; Hiroyuki Isayama; Yosuke Nakai; Takeyuki Watadani; Mariko Tanaka; Tetsuo Ushiku; Nobuhisa Akamatsu; Junichi Kaneko; Junichi Arita; Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  J Gastrointest Surg       Date:  2018-05-15       Impact factor: 3.452

Review 5.  Hilar cholangiocarcinoma: diagnosis, treatment options, and management.

Authors:  Kevin C Soares; Ihab Kamel; David P Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

Review 6.  The role of intraductal ultrasonography in pancreatobiliary diseases.

Authors:  Bo Sun; Bing Hu
Journal:  Endosc Ultrasound       Date:  2016 Sep-Oct       Impact factor: 5.628

7.  Transhepatic Hilar Approach for Perihilar Cholangiocarcinoma: Significance of Early Judgment of Resectability and Safe Vascular Reconstruction.

Authors:  Naohisa Kuriyama; Shuji Isaji; Akihiro Tanemura; Yusuke Iizawa; Hiroyuki Kato; Yasuhiro Murata; Yoshinori Azumi; Masashi Kishiwada; Shugo Mizuno; Masanobu Usui; Hiroyuki Sakurai
Journal:  J Gastrointest Surg       Date:  2016-11-28       Impact factor: 3.452

8.  Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status.

Authors:  Naohisa Kuriyama; Masanobu Usui; Kazuaki Gyoten; Aoi Hayasaki; Takehiro Fujii; Yusuke Iizawa; Hiroyuki Kato; Yasuhiro Murata; Akihiro Tanemura; Masashi Kishiwada; Hiroyuki Sakurai; Shugo Mizuno; Shuji Isaji
Journal:  BMC Cancer       Date:  2020-05-11       Impact factor: 4.430

9.  Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution.

Authors:  Byoung Hyuck Kim; Eui Kyu Chie; Kyubo Kim; Jin-Young Jang; Sun Whe Kim; Do-Youn Oh; Yung-Jue Bang; Sung W Ha
Journal:  Oncotarget       Date:  2017-04-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.